Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Status:
Completed
Trial end date:
2019-05-18
Target enrollment:
Participant gender:
Summary
This is a research study for newly diagnosed multiple myeloma or multiple myeloma has
returned (relapsed). Multiple myeloma is a type of cancer that begins in white blood cells
called plasma cells. Plasma cells make proteins that help fight infections. Current therapy
for multiple myeloma includes high dose chemotherapy and autologous (patient's own cells)
stem cell transplantation.
There will be two parts (or phases) to this study:
The purpose of the first part is to find the highest dose of a drug called lenalidomide
(Revlimid®) that can be given in combination with high dose melphalan without causing severe
adverse events.
The purpose of the second part is to find out the effects of this treatment (good and bad) on
multiple myeloma patients.